On CRSP's fourth-quarter 2024 earnings call, investors' focus will likely be on the sales figure of Casgevy, its first marketed product.

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Cytokinetics (CYTK – Research Report) and ...

On Friday, doctors at Massachusetts General Hospital announced that a 66-year-old New Hampshire man had successfully received ...

Racial disparities in mortality are increasing. This article explores how the production of DNA-edited ethnically diverse ...

Bristol Myers Squibb's FDA nod for Breyanzi (liso-cel) in relapsed/refractory CLL/SLL boosts its CAR T-cell portfolio, ...

The second person ever has received a transplant with a genetically modified pig kidney.

Genesis announced that it has completed its second successful human transplant with a genetically engineered pig kidney, with ...

We expect Moderna MRNA to surpass expectations when it reports fourth-quarter and full-year 2024 earnings on Feb. 14, before ...

A Massachusetts man suffering from end-stage kidney disease has become the second living person to receive a genetically modified pig kidney transplant, marking a major milestone in the field of ...

Duke University cancer researcher Prof Donald McDonnell on BTYSTE and how learning the scientific process at an early age is ...

KBC Group NV grew its stake in Twist Bioscience Co. (NASDAQ:TWST – Free Report) by 71.4% during the 4th quarter, Holdings Channel reports. The firm owned 2,942 shares of the company’s stock after ...

Gene therapies to treat rheumatoid arthritis have evolved slowly, but one is ready to move into human trials and an ...